Pfizer has officially kissed goodbye to its consumer health venture by selling its final 7.3% stake in Haleon for a tidy $3.3 ...

Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA ...

U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...

Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...

Alnylam Pharmaceuticals Inc. won expanded approval for a heart drug that could be the biggest boon yet for the 23-year-old ...

Thanks to the spending growth cap, the U.K. government in December 2024 announced that companies would need to pay a 22.9% ...

Here are three reasons why Pfizer could prove to be a steal of a deal this year. Buying quality stocks at decent valuations ...

Pfizer stock has delivered its long-term shareholders a dividend that has grown for 16 consecutive years. The pace of those ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

Pfizer will sell its remaining stake in British consumer healthcare group Haleon , the companies said on Tuesday.